Health Care Resource Use Among Patients with Advanced Non-Small Cell Lung Cancer in Japan, 2017-2019

• Main Authors: Yasushi Goto, MD, PhD (Author), Kodai Kawamura, MD, PhD (Author), Tatsuro Fukuhara, MD, PhD (Author), Yukiko Namba, MD, PhD (Author), Keisuke Aoe, MD, PhD (Author), Takehito Shukuya, MD, PhD (Author), Takeshi Tsuda, MD (Author), Melissa L. Santorelli, PhD, MPH (Author), Kazuko Taniguchi, MS (Author), Tetsu Kamitani, MD, PhD (Author), Masato Irisawa, PhD (Author), Kingo Kanda, MPharm (Author), Machiko Abe, MS (Author), Thomas Burke, PharmD, PhD (Author), Hiroshi Nokihara, MD, PhD (Author)
• Format: Book
• Published: Elsevier, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACT: Background: First-line immune checkpoint inhibitor (ICI) monotherapy for advanced non-small cell lung cancer (NSCLC) was introduced in Japan in February 2017. Limited information is available since that time regarding health care resource use for NSCLC in Japan, where the hospitalization b...